文献速递神经肿瘤

B7-H3 CAR T细胞联合ONC206抗DIPG的临床前疗效

Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma.
PubMed 文献 · Neuro Oncol · 2026-01-01

该临床前研究在多种DIPG细胞培养和原位异种移植小鼠模型中,测试B7-H3 CAR T细胞联合ONC206的疗效。结果显示联合低效靶比CAR T细胞与IC50浓度ONC206可显著增强体外细胞毒性(P < .003),并在小鼠模型中延长生存期,提示该多药联合方案可行且有效。

要点

  • B7-H3 CAR T细胞单药对DIPG细胞有强细胞毒性,ONC206引起显著线粒体功能障碍。
  • 低效靶比CAR T细胞联合IC50浓度ONC206在体外显著增强细胞毒性(P < .003)。
  • 联合治疗在DIPG异种移植小鼠模型中延长生存期。

核心结论

  • B7-H3 CAR T细胞联合ONC206是針對多種DIPG模型可行且有效的多药联合策略。

研究设计与样本

  • 临床前研究,在多种DIPG细胞培养和原位异种移植小鼠模型中测试B7-H3 CAR T细胞联合ONC206。

主要发现

  • B7-H3 CAR T细胞单药诱导强细胞毒性,ONC206治疗导致DIPG细胞显著线粒体功能障碍。
  • 低效靶比B7-H3 CAR T细胞联合IC50浓度ONC206在体外显著增强细胞毒性(P < .003),并增加IL-2、IL-29、VEGF-A和颗粒酶B水平。
  • ONC206联合单次ICV剂量B7-H3 CAR T细胞的体内联合研究延长了DIPG异种移植小鼠模型的生存期。

临床怎么用

  • 该临床前结果支持进一步临床评估B7-H3 CAR T细胞联合ONC206治疗DIPG。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brain tumor affecting over 300 children annually in the United States. Chimeric antigen receptor (CAR) T cells are a targeted immune effector cell therapy with substantial clinical benefit against hematologic cancers. Against central nervous system (CNS) tumors, CAR T cells targeting B7-H3, a protein highly expressed on DIPG, have rapidly advanced from preclinical studies to clinical trials. BrainChild-03 (NCT04185038), a phase 1 trial of repeatedly delivered intracerebroventricular (ICV) B7-H3-targeting CAR T cells (B7-H3 CAR T cells), demonstrated tolerability and potential efficacy for children and young adults with DIPG. However, clinical benefits were not uniformly seen, and multi-agent treatment strategies may be required against such an aggressive disease. Here, we combined B7-H3 CAR T cells with ONC206, an imipridone molecule also under clinical investigation. METHODS: We tested B7-H3 CAR T cells combined with ONC206 across multiple DIPG cell cultures and orthotopic xenograft mouse models. RESULTS: B7-H3 CAR T cell monotherapy induced robust cytotoxicity while ONC206 treatment resulted in significant mitochondrial dysfunction against DIPG cells. The combination of low effector-to-target ratios of B7-H3 CAR T cells and IC50 concentrations of ONC206 led to significantly enhanced cytotoxicity in vitro (P < .003) and increased IL-2, IL-29, VEGF-A, and Granzyme B levels. In vivo combinatorial studies of ONC206 and a single ICV dose of B7-H3 CAR T cells extended survival in DIPG xenograft mouse models. CONCLUSIONS: B7-H3 CAR T cells combined with ONC206 are a feasible and efficacious multi-agent approach against multiple DIPG models.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Timpanaro A, Song EZ, Toumi R, et al. Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma. Neuro Oncol. 2026. PMID: 41639009. doi:10.1093/neuonc/noag025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。